Missing content? – Request curation!
Request curation for specific Genes, Variants, or PubMed publications.
Have questions, comments, or suggestions? - Let us know!
Email us at : ckbsupport@genomenon.com
| Drug Name | Belimumab |
| Trade Name | Benlysta |
| Synonyms | LymphoStat-B |
| Drug Descriptions |
Benlysta (belimumab) is a monoclonal antibody that neutralizes B-cell activating factor (BAFF; TNFSF13B), potentially leading to increased NK-cell mediated lysis of tumor cells (PMID: 25710310). Benlysta (belimumab) is FDA approved for use in patients with systemic lupus erythematosus (FDA.gov). |
| DrugClasses | |
| CAS Registry Number | 356547-88-1 |
| NCIT ID | C91385 |
| Therapy Name | Drugs | Efficacy Evidence | Clinical Trials |
|---|---|---|---|
| Belimumab | Belimumab | 0 | 0 |
| Belimumab + Rituximab + Venetoclax | Belimumab Rituximab Venetoclax | 0 | 1 |